Compare TG Therapeutics Inc (TGTX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Verisign, Inc. — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Verisign, Inc. trades at $286.99 (market cap $25.51B). The key difference: Verisign, Inc. is far larger — about 3× TG Therapeutics Inc's market cap, and Verisign, Inc. pays a 1.15% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VRSN | |
|---|---|---|
Market Cap | $8.53B | $25.51B |
Sector | Health | Technology |
52-Week High | $59.06 | $310.00 |
52-Week Low | $26.94 | $211.49 |
Enterprise Value | $8.74B | $26.82B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal but strong fundamentals including a 49.77% net income margin and record domain registrations. Recent Q2 2026 earnings beat estimates with EPS of $2.38, though Q4 2025 and Q2 2026 missed expectations. The stock faces headwinds from an antitrust lawsuit filed in September 2026, but institutional buying by firms like BlackRock signals confidence.
Outlook is mixed: bullish analyst consensus with a $328.50 price target suggests 16% upside, supported by AI-driven domain growth and a pending .web delegation. Risks include legal overhangs and competitive pressures. The current valuation at a P/E of 30.64 may limit near-term gains unless earnings accelerate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
